KPTI4:05 PMKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)karyopharm.com
KPTI4:05 PMKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)karyopharm.com
KPTI7:30 AMKaryopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosiskaryopharm.com